Safety and Efficacy of Autologous Platelet-Rich Plasma for Erectile Dysfunction.

• Status: Recruiting
• Trial end date: 2023-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to evaluate changes in vascular parameters and International Index of Erectile Function (IIEF) scores with the administration of Platelet Rich Plasma (PRP) to participants with Erectile Dysfunction (ED)

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Miami
• Collaborator: Acerus Pharmaceutical

Criteria

Inclusion Criteria:

1. Be Male

2. Be 30 to 75 years of age (inclusive).

3. Be able to provide written informed consent.

4. Have a diagnosis of ED due to organic origin for at least 6 months prior to consent.

5. Sexually active in a stable, heterosexual relationship of more than three months duration.

6. IIEF-EF score 11-25 at screening (even if taking a single PDE5).

7. Agree to attempt sexual intercourse at least 4 times per month for the duration of the study without being under the influence of alcohol or recreational drugs.

8. Agree to comply with all study related tests/procedures.

Exclusion Criteria:

1. Previous penile surgery of any kind (except circumcision and condyloma removal), such as penile lengthening, penile cancer surgery, penile plication, grafting.

2. Previous history of priapism or penile fracture

3. Abnormal morning serum testosterone level defined as a value lower than 300 ng/dL (±5%) (indicative of untreated hypogonadism), or greater than 1197 ng/dL (±5%).

4. Current or previous hormone usage, other than prescribed testosterone, clomiphene or thyroid medication. (Subjects with prior or current use of hormonal treatment for prostate cancer are also excluded.

5. Psychogenic ED as determined by study investigator.

6. Anatomical (Peyronie's Disease or penile curvature that negatively influences sexual activity) or neurological abnormalities in the treatment area.

7. Patients using Intra Cavernous Injection (ICI)for management of ED

8. Patients with generalized polyneuropathy, or neurological conditions irrespective of cause, such as severe diabetes, multiple sclerosis or Parkinson's disease.

9. Have a serious comorbid illness/condition/behavior that, in the opinion of the investigator, may compromise the safety or compliance of the subject or preclude successful completion of the study.

10. History of consistent treatment failure with PDE5 inhibitors for therapy of ED.

11. Any history of significant psychiatric disease, such as bipolar disorder or psychosis, greater than one lifetime episode of major depression, current depression of moderate or greater severity. Patients who are currently using Selective Serotonin Reuptake Inhibitor or psychotropic medications.

12. Hemoglobin a1c >9%.